2024 ESC Guidelines for the management of elevated blood pressure and hypertension
The 2024 ESC Guidelines introduce an 'elevated blood pressure' category and a general systolic target of 120–129 mmHg, spanning measurement, drug therapy, device treatment and cardiovascular prevention. This page maps the landmark trials from our register that the guideline cites — grouped by theme.
This guideline cites 7 of the 199 landmark trials in our Cardiology register.
Blood-pressure targets & intensive lowering2
Drug therapy & combinations2
Renal denervation (device therapy)2
- 2023SPYRAL HTN-ON MEDCardiology · HTN · Renal denervationRenal Denervation With the Symplicity Spyral System in Uncontrolled Hypertension on Antihypertensive Medications (pivotal/Expansion cohort)
- 2014SYMPLICITY HTN-3Cardiology · HTN · Renal denervationRenal Denervation in Patients with Resistant Hypertension
Cardiovascular prevention1
- 2000HOPECardiology · Coronary · ACE inhibitorHeart Outcomes Prevention Evaluation